Since the decrease in the survivors with CREB3L1− and PTN+ reflected the changes in malignant degree of the tumors, it is conceivable that the states of CREB3L1 and PTN expression are regarded to be a diagnostic tool serving for predicting a poor prognosis of the brain glioma and evaluating the efficacy of newly targetted molecular drugs. This evidence concerns the gene CREB3L1 and brain glioma.